Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals of Surgical Oncology.
Once a month, Dr. Greene will interview authors and leading experts in surgical oncology. Speaking of SurgOnc® episodes will be available on this page and wherever you listen to your favorite podcasts, including Apple Podcasts, Spotify, Stitcher. iHeartRadio and TuneIn.
Episode 21: “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma”
March 9, 2021
Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.”
Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.
Episode 20: “Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change”
February 9, 2021
Rick Greene, MD, and Ken Tanabe, MD, discuss the need for surgical oncologists to remain focused on providing optimal care for our cancer patients while managing the demands that the COVID-19 pandemic continues to impose. Dr. Tanabe is author of, “Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change.”
Dr. Tanabe is a Professor of Surgery at Harvard Medical School and Chief, Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital. Dr. Tanabe is also Deputy Editor of the Annals of Surgical Oncology.
Episode 19: “Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade”
January 14, 2021
Rick Greene, MD and Charlotte Ariyan, MD, PhD, discuss survival outcomes in patients with metastatic melanoma who were selected for surgery following checkpoint blockade. Dr. Ariyan is author of, “Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.”
Dr. Ariyan is Associate Professor of Surgery, Weill Cornell Medical College, and a Surgeon with clinical expertise in melanoma and soft tissue sarcoma, at Memorial Sloan Kettering Cancer Center, New York, NY. Dr. Ariyan is also Section Editor, Sarcoma, at the Annals of Surgical Oncology.
Episode 18: “Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial”
December 8, 2020
Rick Greene, MD and Katie Egan, MD discuss the use of an educational intervention to decrease opioid consumption among breast surgery patients. Dr. Egan is author of the article, “Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial.”
Dr. Egan is Plastic and Reconstructive Surgery Resident at The University of Kansas Medical Center in Kansas City, KS.
November 10, 2020
Rick Greene, MD and Anna Weiss, MD discuss clinical trials that have defined the role of neoadjuvant endocrine therapy in patients with estrogen receptor-positive breast cancer. Dr. Weiss is author of “The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer.”
Dr. Weiss is Assistant Professor of Surgery at Harvard Medical School, Boston, MA.
Episode 15: Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies
August 11, 2020
Rick Greene, MD and Giorgos Karakousis, MD discuss the impact of immune checkpoint and BRAF/MEK pathway inhibitors on outcomes and melanoma care at a national population level in patients diagnosed with clinical stage III melanoma. Dr. Karakousis is author of, “Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.”
Dr. Karakousis is Associate Professor of Surgery at the Hospital of the University of Pennsylvania, Philadelphia, PA.
Episode 14: Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases
July 14, 2020
Rick Greene, MD, and Michael D’Angelica, MD discuss the relationship between hepatic parenchymal disease and recurrence after colorectal liver metastases resection, which has not been well defined. Dr. D’Angelica is author of, “Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases.”
Dr. D’Angelica holds the Enid A. Haupt Chair in Surgery at Memorial Sloan Kettering Cancer Center and is Professor of Surgery at Weill Medical College of Cornell University, New York.
Episode 13: Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility
June 18, 2020
Rick Greene, MD and Elizabeth Grubbs, MD, MS discuss an analysis of the applicant pool of complex general surgical oncology (CGSO) fellowships and how it has changed over the last decade.
Dr. Grubbs is Associate Professor, Program Director of Complex General Surgical Oncology Fellowship, Vice Chair of Education, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Episode 12: Symptom burden at the end-of-life for neuroendocrine tumors: an analysis of 2,579 prospectively collected patient-reported outcomes.
May 12, 2020
Rick Greene, MD and Julie Hallet, MD, MSc discuss the moderate-to-severe symptoms observed to steeply increase as death nears for patients with neuroendocrine tumors (NETs), which highlight an opportunity for improved management.
Dr. Hallet is Assistant Professor, Surgical Oncology, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada.
Episode 11: Germline Genetic Testing: What the Breast Surgeon Needs to Know
April 7, 2020
Rick Greene, MD and Jennifer Plichta, MD discuss the potential benefit for women from genetic testing for BRCA1, BRCA2, and other breast cancer genes and the knowledge needed by breast surgeons to facilitate testing and counseling.
Dr. Plichta is author of, “Germline Genetic Testing: What the Breast Surgeon Needs to Know.”
Dr. Plichta is an Assistant Professor of Surgery, Division of Surgical Oncology, Duke Surgery, Duke University School of Medicine, Durham, NC.
Episode 10: Maintenance of Certification and Continuing Medical Education: Are They Still Required?
March 10, 2020
Rick Greene, MD and Marissa M. Howard-McNatt, MD discuss how the requirements for maintenance of certification (MOC) and CME changed in 2018, and review the options for completing these requisites.
Mariss M. Howard-McNatt, MD is author of, “Maintenance of Certification and Continuing Medical Education: Are They Still Required?”
Marissa M. Howard-McNatt, MD is an Associate Professor of Surgery Sciences – Oncology, Wake Forest School of Medicine, Winston-Salem, NC. She is the Director of the Breast Care Center and specializes in breast surgery.
Episode 9: Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer
February 11, 2020
Dr. Rick Greene and Dr. Jacqueline S. Jeruss discuss the potential impact of treatment on the future fertility of young breast cancer patients and review guidelines provided to address reproductive health in conjunction with a breast cancer diagnosis.
Dr. Jeruss is an Associate Professor of Surgery at Departments of Surgery, Pathology, and Biomedical Engineering, University of Michigan, Ann Arbor, MI. She specializes in the care of patients with benign and malignant breast disease.